Praxis Precision's Phase 2/3 POWER1 Study Of Vormatrigine In Focal Onset Seizures Did Not Meet Its Primary Endpoint, Though 50% Response Rate Was Achieved And Seizure Reduction Was More Pronounced At 30 Mg Dose In Second Half Of The Study

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure

Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced

Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10%

Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study

Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (FOS).